Article History
Received: 9 October 2018
Accepted: 29 August 2019
First Online: 14 September 2019
Ethics approval and consent to participate
: The study was approved by the University of New South Wales Human Research Ethics Panel (HC17011). Information was provided about the study to potential participants and consent was implied if the participants completed and submitted the survey.
: Not applicable
: Dr. Holly Seale has previously received funding from drug companies for investigator driven research and consulting fees to present at conferences/workshops and develop resources (bio-CSL/Sequiris, GSK and Sanofi Pasteur). She has also participated in advisory board meeting for Sanofi Pasteur. Dr. Seale is an editorial board member for BMC Infectious Diseases. The other authors do not have anything to declare.